Early access for Pherecydes' anti-S. aureus phages in France
Pherecydes Pharma (FR0011651694 - ALPHE) has been granted AAC Early Access Program approval by France’s Agence Nationale de Sécurité du Médicament et des produits de santé (ANSM) for its anti-Staphylococcus aureus (S. aureus) phages.
The new AAC system (formerly nominative authorization for early access - ATU), introduced in July 2021 by the ANSM, allows certain categories of sick patients in France with no therapeutic solutions to benefit from drugs yet to be granted marketing approval.
"Highlights the critical need for treatments for antibiotic-resistant infections"To date, Pherecydes has treated more than 50 patients within the framework of compassionate treatment under the supervision of the ANSM, excluding AAC status, including 28 with its anti-S. aureus phages.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze